Saving Eyes: Iveric Bio is investing in fighting retinal diseases

Iveric Bio has a drug in its pipeline that has the company excited for the future: Zimura.

Zimura is an investigational complement C5 inhibitor that is designed to decrease the activation of inflammasomes and the formation of membrane attack complex (MAC). The company believes Zimura could treat Geographic Atrophy (GA) secondary to dry age-related macular degeneration (AMD) by preventing or slowing the degeneration of retinal pigment epithelial cells.